A year after opening its first ‘Empax’ centre in Leederville, Western Australia, Emyria Ltd (ASX:EMD) has opened a second – this time within the eminent mental health hospital, the Perth Clinic.

Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.

In this way, it aims to expand its provision of programs supporting patients with both PTSD and treatment-resistant depression – including through psychedelic-assisted therapies – by 50%.

The first 2 fully funded patients will be commencing treatment on 14 April, with this underscoring both the activation of the Perth Clinic site and the company’s intention to roll out a broader strategy to meet clinical demand – with the latter also reflecting structural changes in mental health care funding.

The centre’s location within a licensed facility has been facilitated to ensure Emyria meets the requirements of payers set to fund Empax treatment. The company is now looking to potential expansion of ‘Empax’ into the eastern states.

Executive chair Greg Hutchinson said the company was responding to an environment of increased need.

“We are responding to growing patient demand and the expectations of major healthfunders,” he said Greg Hutchinson.

More market news

Kowtow: “Biggest day in financial history” on Trump’s tariffs retreat

Meet GeoGeorge: The HotCopper poster so accurate he got hired as an analyst

He continued: “Our expansion into licensed hospital settings demonstrates Emyria’s capacity to deliver scalable, evidence-based mental health care treatments.”

At 10:25 AEST, Emyria was trading at 3 cents – a rise of 3.45% since the market opened.

Join the discussion: See what HotCopper users are saying about Emyria and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.